Author(s)

Joaquín Lasierra-Cirujeda^1*, María José Aza Pascual-Salcedo², María Mercedes Aza Pascual-Salcedo³

¹C. Medicine Hematology, Logrono, Spain.
²The Rioja and Pharmaceutical Act, Ministry of Health, The Rioja Regional Government, Logrono, Spain.
³Aragon Health Service, Zaragoza, Spain.

The purpose of this prospective study is to determine the relative incidence of Alzheimer’s disease in patients treated for at least three years, with sulodexide (n = 46, 76.48 ± 7.02 years old) or acenocoumarol (n = 47, 78.21 ± 6.66 years old) in order to prevent primary and secondary venous thromboembolism and atherothrombotic disease. In the sulodexide group, there was an apparent prevention of cognitive and behavioural impairment (relative incidence: 2.02) compared with acenocoumarol group (relative incidence: 4.86). The favourable results in sulodexide group may be related to their pharmacodynamic actions of inhibition of PAI-1, which may interfere with the pathogenesis of Alzheimer’s disease, and to the role of glutathione and PAI-1 in the β-amyloid system in the brain.

Sulodexide, Alzheimer’s Disease, Glutathione, t-PA, PAI-1, Plasminogen, Plasmin

Lasierra-Cirujeda, J. , Pascual-Salcedo, M. and Pascual-Salcedo, M. (2016) Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study. World Journal of Cardiovascular Diseases, 6, 54-71. doi: 10.4236/wjcd.2016.62007.